Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer

Fig. 7

PKP3 promotes OTUB1 expression by enhancing its mRNA stability. A Relative luciferase activity of the OTUB1 promoter in NSCLC cells transfected with PKP3-overexpressing constructs. Firefly luciferase activity was normalized to Renilla activity. B Time-course qRT-PCR analyses of the relative abundance of OTUB1 in control or PKP3-overexpressing H1650 cells treated with actinomycin D (10 μg/ml). C PKP3 IP assay to detect OTUB1 mRNA in A549 cells. D IP analysis of the interaction between FXR1 and PKP3 in A549 cells. E The expression of OTUB1 in FXR1-silenced SK-MES-1 cells with or without PKP3 overexpression, as determined by qRT-PCR (left) and western blotting (right). F Time-course qRT-PCR analyses of the relative abundance of OTUB1 mRNA in FXR1-silenced SK-MES-1 cells with or without PKP3 overexpression after treatment with actinomycin D (10 μg/ml). G PKP3 IP assay to detect OTUB1 in A549 cells with or without FXR1 knockdown. H Schematic diagram showing the sequence of myc-tagged full-length PKP3 and myc-tagged PKP3ΔC lacking repeat domains at its C-terminus. I The interaction between PKP3 constructs (full-length PKP3 or PKP3ΔC) and OTUB1 mRNA was analyzed by qRT-PCR after IP. The enrichment of myc-tagged proteins and coprecipitated FXR1 were also analyzed. J Time-course qRT-PCR analyses of the relative abundance of OTUB1 in H1650 cells transfected with full-length PKP3 or PKP3ΔC after treatment with actinomycin D (10 μg/ml). Data represent the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. P values were determined by unpaired Student’s t test (A and B) and one-way ANOVA with Tukey’s post hoc test (E, F and J)

Back to article page